Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy‐confirmed NAFLD
Authors:
- 28 April 2021
- journal article
- research article
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
- Vol. 28 (7) , 593-603
Abstract
Background: The presence of significant liver fibrosis is a key determinant of long‐term prognosis in non‐alcoholic fatty liver disease (NAFLD). We aimed to develop a novel machine learning algorithm (MLA) to predict fibrosis severity in NAFLD and compared it with the most widely used non‐invasive fibrosis biomarkers.Methods: We used a cohort of 553 adults with biopsy‐proven NAFLD, who were randomly divided into a training cohort (n = 278) for the development of both logistic regression model (LRM) and MLA, and a validation cohort (n = 275). Significant fibrosis was defined as fibrosis stage F ≥ 2. MLA and LRM were derived from variables that were selected using a least absolute shrinkage and selection operator (LASSO) logistic regression algorithm.Results: In the training cohort, the variables selected by LASSO algorithm were body mass index, pro‐collagen type III, collagen type IV, aspartate aminotransferase and albumin‐to‐globulin ratio. The diagnostic accuracy of MLA showed the highest values of area under the receiver operator characteristic curve (AUROC: 0.902, 95% CI 0.869‐0.904) for identifying fibrosis F ≥ 2. The LRM AUROC was 0.764, 95% CI 0.710‐0.816 and significantly better than the AST‐to‐Platelet ratio (AUROC 0.684, 95% CI 0.605‐0.762), FIB‐4 score (AUROC 0.594, 95% CI 0.503‐0.685) and NAFLD Fibrosis Score (AUROC 0.557, 95% CI 0.470‐0.644). In the validation cohort, MLA also showed the highest AUROC (0.893, 95% CI 0.864‐0.901). The diagnostic accuracy of MLA outperformed that of LRM in all subgroups considered.Conclusions: Our newly developed MLA algorithm has excellent diagnostic performance for predicting fibrosis F ≥ 2 in patients with biopsy‐confirmed NAFLD.Keywords
Funding Information
- National Natural Science Foundation of China (82070588)
This publication has 29 references indexed in Scilit:
- Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver DiseaseGastroenterology, 2016
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- Visceral Obesity Predicts Significant Fibrosis in Patients With Nonalcoholic Fatty Liver DiseaseMedicine, 2015
- Markers of Collagen Remodeling Detect Clinically Significant Fibrosis in Chronic Hepatitis C PatientsPLOS ONE, 2015
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2015
- Plasma Pro‐C3 (N‐terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis CLiver International, 2014
- The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of GastroenterologyGastroenterology, 2012
- Disease-Free Survival after Hepatic Resection in Hepatocellular Carcinoma Patients: A Prediction Approach Using Artificial Neural NetworkPLOS ONE, 2012
- The NAFLD fibrosis scoreHepatology, 2007
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005